|
注册号: Registration number: |
ChiCTR2300069051 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-06 11:36:30 |
|
注册时间: Date of Registration: |
2023-03-06 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
上海重中之重临床医学中心——类风湿关节炎专病队列 |
|
Public title: |
Observation on patients with rheumatoid arthritis and its complications: a multi-center, prospective cohort study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
上海重中之重临床医学中心——类风湿关节炎专病队列 |
|
Scientific title: |
Observation on patients with rheumatoid arthritis and its complications: a multi-center, prospective cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨雅竹 |
研究负责人: |
梁倩倩 |
|
Applicant: |
Yang Yazhu |
Study leader: |
Liang Qianqian |
|
申请注册联系人电话: Applicant telephone: |
+86 159 2199 6378 |
研究负责人电话:
Study leader's |
+86 189 1776 3347 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
522420463@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
liangqianqiantcm@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国上海市宛平南路725号 |
研究负责人通讯地址: |
中国上海市宛平南路725号 |
|
Applicant address: |
725 Wanping Road South, Shanghai, China |
Study leader's address: |
725 Wanping Road South, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海中医药大学附属龙华医院 |
||
|
Applicant's institution: |
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
上海中医药大学附属龙华医院 |
||
|
Affiliation of the Leader: |
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022LCSY107号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海中医药大学附属龙华医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethical Committee of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-01-19 00:00:00 | ||
|
伦理委员会联系人: |
刘胜 |
||
|
Contact Name of the ethic committee: |
Liu Sheng |
||
|
伦理委员会联系地址: |
中国上海市宛平南路725号 |
||
|
Contact Address of the ethic committee: |
725 Wanping Road South, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 64385700 1318 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海中医药大学附属龙华医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国上海市宛平南路725号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
725 Wanping Road South, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市重中之重临床医学中心 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Top Clinical Medical Center |
||||||||||||||||||||||
|
研究疾病: |
类风湿关节炎 |
||||||||||||||||||||||
|
Target disease: |
rheumatoid arthritis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
通过队列研究明确RA并发症中可供测量和评价的关键生物学指标,发掘影响RA并发症发生发展的干预因素,探究RA并发症的相关病理机制,构建并发症疾病预测模型,为控制RA进展、防治RA并发症的干预策略奠定理论基础。 |
||||||||||||||||||||||
|
Objectives of Study: |
Through cohort study, identify the key biological indicators that can be measured and evaluated in RA complications, explore the intervention factors that affect the occurrence and development of RA complications, explore the relevant pathological mechanism of RA complications, and build a disease prediction model for complications, laying a theoretical foundation for intervention strategies to control the progress of RA and prevent and treat RA complications. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.因其他原发疾病不能完成队列研究者; 2.原发疾病对结局判断有影响的疾病,如强直性脊柱炎、红斑狼疮、银屑病关节炎等自身免疫性疾病; 3.认知障碍等精神类疾病患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those who cannot complete the cohort study due to other primary diseases; 2. Primary diseases that affect the outcome judgment, such as ankylosing spondylitis, lupus erythematosus, psoriatic arthritis and other autoimmune diseases; 3. Patients with mental disorders such as cognitive impairment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-19 00:00:00至 To 2026-01-18 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-03-06 00:00:00 至 To 2024-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |